# A Phase Ib/II Study to Evaluate Multiple Combination Therapies of FWD1802 in Patients With ER+/HER2- BC

Source: https://onco.cc/trials/nct07002177/  
OnCo record `nct07002177` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Palbociclib, Ribociclib, Abemaciclib and Everolimus in advanced solid tumours, run by Forward Pharmaceuticals Co., Ltd., now recruiting.

## Summary

A Phase Ib/II Study to Evaluate Multiple Combination Therapies of FWD1802 in Patients With ER+/HER2- BC is a phase 1/2 interventional study registered as NCT07002177 by Forward Pharmaceuticals Co., Ltd., with 196 participants planned, started 2025-06-01 and due to reach its primary completion in 2028-05-01. Interventions recorded: FWD1802, Palbociclib 125mg, Ribociclib 200Mg Oral Tablet, Abemaciclib 150 MG and Everolimus 10 mg.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07002177
- Phase: 1/2
- Setting: An Open-label, Multicenter, Phase Ib/II Clinical Study to Evaluate the Safety and Efficacy of Multiple Combination Therapies With FWD1802 in Subjects With ER-positive/HER2-negative Unresectable Locally Advanced or Metastatic Breast Cancer
- Sponsor: Forward Pharmaceuticals Co., Ltd.
- Enrolled: 196

## Sources

- ClinicalTrials.gov NCT07002177: https://clinicaltrials.gov/study/NCT07002177

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Abemaciclib](https://onco.cc/drugs/abemaciclib/), [Everolimus](https://onco.cc/drugs/everolimus/), [Palbociclib](https://onco.cc/drugs/palbociclib/), [Ribociclib](https://onco.cc/drugs/ribociclib/)
- companies: [Forward Pharmaceuticals](https://onco.cc/companies/forward-pharmaceuticals/)

---
JSON: https://onco.cc/api/v1/entities/nct07002177.json